Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027

Loading news article.

Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027 | WAPE

Evommune Announces First Patient Dosed In Phase 2b Trial Of EVO756 For Migraine Prevention, Enrolling Approximately 330 Patients; Top-Line Data Expected In 2027

Article summary

Related companies

Comments —